GLP-1 Lab Guide · FormBlends network
Know which blood tests matter on a GLP-1, and what your results mean.
A1c, glucose, lipids, kidney, liver, thyroid and more: what each measures, why a prescriber orders it, the reference ranges with their source, and a tracker that stays in your browser.
- 33
- common tests you can track in the browser, with a trend line each
- Tests you can track in your browser with a trend line. Nothing is uploaded.
- None
- scheduled labs are required by the GLP-1 labels; they set triggers, not intervals
- The GLP-1 labels require no scheduled labs. Tests are ordered for a reason, not a calendar.
- 6.5%
- A1c diagnostic cut point for diabetes
- The A1c level at which diabetes is diagnosed.
Start here
Three ways in, depending on what you need right now
- 01Lab trackerEnter dated results for 33 common tests, see a trend line per test, export CSV. Stays in your browser.
- 02Pre-therapy lab checklist: what is usually drawn before a first GLP-1 prescription, and where each item comes fromNo GLP-1 label requires a blood test before you start. Most prescribers order a standard panel anyway.
- 03Browse labs16 pages, most recently updated September 4, 2026
Interactive
Calculators
Each runs in your browser, shows its formula, and prints a dated assumptions note. Nothing you type leaves the page.
CalculatorLab tracker
Enter dated results for 33 common tests, see a trend line per test, export CSV. Stays in your browser.
CalculatorPre-visit lab checklist
Pick your therapy stage and conditions, get a printable list of labs and questions to ask about.
Reading
Start with these
Each page opens with a plain-English summary, a figure drawn from the data, the numbers that matter, and what it means if you're considering treatment.
Guides
Pre-therapy lab checklist: what is usually drawn before a first GLP-1 prescription, and where each item comes from
You'll get: No GLP-1 label requires a blood test before you start. Most prescribers order a standard panel anyway.
A one-page baseline list for semaglutide or tirzepatide: the tests most prescribers order, the tests the labels specifically do not ask for, the questions that matter more than any lab, and a printable checklist builder that adapts to your stage and conditions.
Guides
Lab monitoring calendar for GLP-1 therapy: what is repeated, when, and which triggers move the date
You'll get: The GLP-1 labels set no lab schedule. They set one trigger: check kidney function if vomiting or diarrhoea is draining you.
A phase-by-phase calendar for labs on semaglutide or tirzepatide: baseline, the first 12 weeks, months 3 to 12, and beyond a year. Built from the label re-check instruction, the ADA intervals for diabetes, KDIGO for kidney disease, and the symptom triggers that bring a test forward. With a browser-only tracker.
Labs
Hemoglobin A1c on GLP-1 therapy: what it measures, the cut points, and how often it is repeated
You'll get: A1c shows your average blood sugar over about three months. It does not need fasting.
A1c is the three-month average of blood glucose. Why it is drawn before semaglutide or tirzepatide, the diagnostic cut points from MedlinePlus and the ADA, the ADA repeat schedule, and the conditions that make the number unreliable.
Labs
Comprehensive metabolic panel (CMP): the 14 tests, their common ranges, and what each one is doing on a GLP-1 baseline
You'll get: The CMP is 14 tests from one tube: blood sugar, kidney function, salts, liver enzymes and proteins.
The CMP bundles glucose, kidney function, electrolytes, liver enzymes and proteins into one draw. What each of the 14 results means, the MedlinePlus ranges, why it is the standard baseline before semaglutide or tirzepatide, and which parts the labels ask prescribers to re-check.
Labs
Kidney function on GLP-1 therapy: creatinine, eGFR, the KDIGO categories, and the label's dehydration warning
You'll get: Creatinine and eGFR are the two kidney numbers on every metabolic panel.
Creatinine and eGFR are the two kidney numbers on every metabolic panel. The MedlinePlus creatinine range, the KDIGO 2024 eGFR categories, why every semaglutide and tirzepatide label tells prescribers to monitor renal function during vomiting or dehydration, what the FLOW trial showed, and the ADA annual screening rule for diabetes.
Live updates
What changed since this site was written
Sources checked October 23, 2026, refreshed every six hours.
Newest on PubMed
Papers indexed in the last year matching laboratory monitoring (489 in total).
- Pharmacy students' knowledge and attitudes regarding GLP-1 receptor agonist adverse effects in obesity management: a cross-sectional study
Libyan J Med · December 31, 2026 · PubMed 42886550
- GLP-1 Receptor Agonists and Cancer Risk in Obesity Treatment
Obes Rev · October 21, 2026 · PubMed 42906947
- Exploring heterogeneous treatment effects for GLP-1 receptor agonists in patients with type 2 diabetes
Am J Epidemiol · October 20, 2026 · PubMed 42901472
- Real-world observational study evaluating metabolic and kidney outcomes in patients living with chronic kidney disease and type 2 diabetes mellitus with obesity prescribed tirzepatide
Diabet Med · October 19, 2026 · PubMed 42897718
- Erratum. 1800-P: GLP-1 Use in Type 1 Diabetes Patients: Assessing Changes in HbA1c, Body Weight, and Cardiovascular Disease Risk Reduction. Diabetes 2026;75(Suppl. 1):1800-P
Diabetes · October 16, 2026 · PubMed 42886737
FDA and enforcement tracker
FormBlends research feed, data as of September 4, 2026.
September 1, 2026 · Adverse-event report update
FDA GLP-1 concerns page updated: 990 adverse-event reports for compounded semaglutide and >730 for compounded tirzepatide (as of May 31, 2026); border screening and fake-pharmacy labelsAugust 28, 2026 · Label or price event
FDA approves Mounjaro (tirzepatide) to reduce MACE risk in adults with type 2 diabetes (SURPASS-CVOT)August 27, 2026 · Court decision
Fifth Circuit affirms summary judgment for FDA in both GLP-1 shortage cases (Nos. 25-10600 tirzepatide; 25-10758 semaglutide)August 24, 2026 · FDA warning letter
FDA warning letters to five peptide vendors: Peak Performance Peptides (735127), Royal Peptides (734884), NuScience Peptides (733652), Peptide Partners (735063), TXP Innovations dba Tex Peptides (735067)August 24, 2026 · FDA warning letter
FDA warning letter: TXP Innovations LLC dba Tex Peptides (Unapproved New Drugs/Misbranded)
Compounded price index
Median all-in cash price per 28 days across providers, as of September 3, 2026.
- semaglutide, month 1 at 0.25 mg/week
- $197
- median of 14 providers
- semaglutide, month 4 at 1 mg/week
- $199
- median of 13 providers
- tirzepatide, month 1 at 2.5 mg/week
- $268
- median of 14 providers
- tirzepatide, month 4 at 5 mg/week
- $299
- median of 12 providers
- September 3, 2026: Index, All, baseline 51 rows. First weekly snapshot. Changes against this baseline will be listed here with the date they were observed.
PubMed lists come from NCBI E-utilities and are not reviewed by us before they appear. Feeds are FormBlends Research data (CC BY 4.0); FormBlends sells compounded GLP-1 drugs and appears in the price index under the same rules as every other provider. Compounded drugs are not FDA approved.
Browse
Sections
20 pages across 2 sections, each sourced to a label, a trial or a dated manufacturer page.
Labs
You'll get: 16 sourced pages, each with a plain-English opener
A1c is the three-month average of blood glucose. Why it is drawn before semaglutide or tirzepatide, the...
Guides
You'll get: 4 sourced pages, each with a plain-English opener
A one-page baseline list for semaglutide or tirzepatide: the tests most prescribers order, the tests the...
What the labels ask for, and what they do not
The semaglutide and tirzepatide labels ask prescribers to monitor kidney function when someone is losing fluid, to watch for pancreatitis and gallbladder symptoms, and to adjust insulin or sulfonylurea doses. They do not ask for routine calcitonin, thyroid ultrasound, lipase or amylase, and they say so in plain words. Each page here quotes the relevant label sentence so you know which tests are expected and which are a judgement call.
How to use the ranges on this site
Every range is copied from a named public source, mostly MedlinePlus and the KDIGO 2024 kidney guideline, with the date we checked it. Laboratories set their own reference intervals for their own methods and populations, and the interval printed on your report is the one that applies to your sample. Use these pages to understand the report, then take questions to the clinician who ordered it.